GILEAD SCIENCES, INC.
10% Owner · Arcus Biosciences, Inc.
Every open-market stock purchase GILEAD SCIENCES, INC. has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- ASMB+35.2% vs price paidASSEMBLY BIOSCIENCES, INC.
One purchase totalling $20.1M at an average of $21.37 per share; the stock last traded at $28.90. See all insider buying in ASMB →
Avg price paid$21.37Latest price$28.90Market cap$572.6M - RCUSArcus Biosciences, Inc.
One purchase totalling $15.0M at an average of $11.00 per share. See all insider buying in RCUS →
Avg price paid$11.00Latest price—Market cap$3.8B - XLO+863.8% vs price paidXilio Therapeutics, Inc.
2 purchases totalling $2.2M at an average of $0.98 per share; the stock last traded at $9.44. See all insider buying in XLO →
Avg price paid$0.98Latest price$9.44Market cap$56.5M
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving GILEAD SCIENCES, INC. or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from GILEAD SCIENCES, INC.'s Form 4 filings on SEC EDGAR (CIK 882095) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.